Loading...
•
Jun 30, 2020
Ashland Q3 2020 Earnings Report
Ashland's financial results for the third quarter of fiscal 2020 were announced, showing resilience despite global economic uncertainty.
Key Takeaways
Ashland reported sales of $574 million, a 10% decrease compared to the prior-year quarter. Net income was $37 million, and adjusted EBITDA increased to $143 million. The company saw improved performance in its consumer business units, particularly in pharmaceutical excipients and additives for hand sanitizers, while industrial businesses showed signs of recovery in June.
Sales were $574 million, down 10% year-over-year.
Net income reached $37 million.
Adjusted income from continuing operations, excluding intangibles amortization expense, was $68 million, up from $64 million in the prior-year quarter.
Adjusted EBITDA rose to $143 million, up from $140 million in the prior-year quarter,
Ashland
Ashland
Ashland Revenue by Segment
Revenue by Segment
Life Sciences Revenue
CapyFin.comPersonal Care Revenue
CapyFin.comSpecialty Additives Revenue
CapyFin.comIntermediates Revenue
CapyFin.com Forward Guidance
Chairman and CEO Guillermo Novo will provide commentary on the outlook for Ashland during the conference call with securities analysts on Wednesday, July 29, 2020.
Revenue & Expenses
Visualization of income flow from segment revenue to net income